title: [Comparing the effectiveness of different treatment modalities on the smoking cessation rates].
abstract: The social patterns of smoking have changed significantly in the past two decades but smoking is still as prevalent in the lowest socioeconomic groups as it was widespread. For the solution of this enormous problem many kinds of treatment modalities have been proposed but there is no single successful method for quitting. To determine the smoking cessation rates with behavioural treatment, behavioural + pharmacological treatments and compare the differences between each approaches. 371 smokers were prospectively evaluated between 2004 and 2008. At the beginning subjects were classified into two groups: behavioral treatment group (I) and pharmacological + behavioural treatment group (II). Numbers of patients per group were 88 and 283 respectively. According to pharmacological therapy group II was also divided into three subgroups: nicotine replacement treatment (NRT) (regardless of the type and dosage) (IIa), bupropion (IIb) and combination treatment modalities group (IIc). Numbers of patients per subgroups were 185, 70 and 28 respectively. All of the patients were attended the one year follow up visits. According to the baseline characteristics there was no significant difference between the groups and subgroups. At the end of the fist year, in group I smoking cessation rate was 41% and in group II 51% and this was not statistically significant (p< 0.05). In the sub group analysis the success rates for group IIa, IIb and IIc; 44.8%, 62.8% and 64% respectively and bupropion is significantly superior to the NRT (p= 0.01). In study subjects, smoking cessation rates were less with comorbid diseases (p= 0.004), baseline airway obstruction (p= 0.04) and high CO levels (p= 0.008). Results of this analysis confirm that, there is a significant difference between pharmacological treatment and behavioral treatments. Additionally, in the pharmacological approaches, bupropion seems to be superior. Besides, comorbid conditions have been a huge problem to solve.
authors.affiliation: Department of Chest Diseases, Faculty of Medicine, Ankara Üniversity, Ankara, Turkey. zponen@yahoo.com
authors.forename: Zeynep Pınar
authors.initials: ZP
authors.lastname: Onen
authors.forename: Elif
authors.initials: E
authors.lastname: Sen
authors.forename: Banu
authors.initials: B
authors.lastname: Eriş Gülbay
authors.forename: Ayperi
authors.initials: A
authors.lastname: Oztürk
authors.forename: Oznur
authors.initials: O
authors.lastname: Akkoca Yıldız
authors.forename: Turan
authors.initials: T
authors.lastname: Acıcan
authors.forename: Sevgi
authors.initials: S
authors.lastname: Saryal
authors.forename: Gülseren
authors.initials: G
authors.lastname: Karabıyıkoğlu
mesh_terms: D000328:Adult; D016642:Bupropion / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D009538:Nicotine / Q000008:administration & dosage / Q000627:therapeutic use*; D011615:Psychotherapy, Group; D016540:Smoking Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D016642:Bupropion; D009538:Nicotine